Pharm-Rx Tacrolimus

Product families

Other characteristics

Markets

Healthcare & Pharma

Definition

Tacrolimus contains NLT 98.0% and NMT 102.0% of tacrolimus (C44H69NO12), calculated on the anhydrous and solvent-free basis.

Technology

Pharmaceuticals & Nutraceuticals

FDA Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Storage Information

Preserve in tight containers. Store at controlled room temperature.

USP Reference Standards

USP Tacrolimus Related Compound A RS(E)-8-Ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-[(E)-2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21-(4H,23H)-tetrone. C43H69NO12 792.02(ERR 1-Sep-2021) USP Tacrolimus 8-epimer RS(3S,4R,5S,8S,9E,12S,14S,15R,16S,18R,19R,26aS)-8-Allyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone. C44H69NO12 804.03 (ERR 1-Sep-2021) USP Tacrolimus 8-propyl Analog RS(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-{(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone. C43H69NO12 792.01 and tacrolimus 8-propyl analog (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R, 19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24, 25,26,26a-Hexadecahydro-5,19-dihydroxy-3-{(E)-2- [(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3H-pyrido[2,1-c][1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone. C44H71NO12 806.03

Show in full